Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HCC × atezolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 49 Carcinoma, Hepatocellular 27 Breast Neoplasms 24 Small Cell Lung Carcinoma 17 Triple Negative Breast Neoplasms 16 Lung Neoplasms 16 Urinary Bladder Neoplasms 14 Melanoma 14 Neoplasms 13 Neoplasm Metastasis 13 Colorectal Neoplasms 13 Carcinoma, Transitional Cell 13 Uterine Cervical Neoplasms 9 Head and Neck Neoplasms 7 Carcinoma, Renal Cell 7 Stomach Neoplasms 6 Recurrence 6 Prostatic Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Sarcoma 5 Liver Neoplasms 5 Carcinoma, Squamous Cell 5 Ovarian Neoplasms 4 Mesothelioma, Malignant 4 Carcinoma, Merkel Cell 4 Solid Tumors 3 Rectal Neoplasms 3 Lymphoma, Follicular 3 Lymphoma 3 Gastrointestinal Neoplasms 3

Interventions

nimotuzumab 1 atezolizumab 1 Radiotherapy 1 Radiosurgery 1 Immune Checkpoint Inhibitors 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡